Checkpoint Inhibitor Response Prediction Using TMB and MHC-I LOH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting treatment outcomes with immunotherapy, particularly checkpoint inhibitors, are limited by the complexity of factors affecting immune responses in cancer, leading to inaccurate selection of patients and therapeutic regimens.
Innovation Solution
Combining tumor mutation burden (TMB) with loss of heterozygosity (LOH), specifically in MHC Class I genes, to predict patient response to checkpoint inhibitors, identifying high TMB without LOH as indicative of a positive outcome and high TMB with LOH as indicative of a poor outcome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If TMB alone is used to predict response to checkpoint inhibitors, then the prediction is simple and quick, but the accuracy is insufficient leading to incorrect patient selection
Solution Approach 1:
The patent combines TMB assessment with LOH status evaluation of MHC Class I genes to create a composite prediction model. This merging of two biomarkers (TMB and LOH) resolves the contradiction by improving prediction accuracy through multi-factor analysis while maintaining a relatively streamlined clinical workflow compared to more complex genomic profiling approaches.
2Measurement precision
If comprehensive genomic analysis is performed to improve prediction accuracy, then the prediction becomes more accurate, but the time and resource consumption increases
Solution Approach 1:
The patent extracts and focuses specifically on two critical genomic features (TMB and MHC Class I LOH status) from the comprehensive genome, rather than analyzing the entire genomic landscape. This extraction approach maintains high prediction accuracy by concentrating on the most predictive elements while significantly reducing the time and computational resources required compared to whole-genome or whole-exome sequencing.
3Reliability
If TMB is increased to improve immune response, then the potential for immunotherapy response increases, but the risk of immune evasion through LOH also increases
Solution Approach 1:
The patent applies preliminary anti-action by assessing LOH status of MHC Class I genes before initiating immunotherapy based on TMB. This pre-treatment evaluation prevents the harmful effect of immune evasion by identifying patients who have already developed mechanisms to escape immune surveillance, thereby avoiding ineffective or wasteful treatment while protecting against the development of resistance by selecting appropriate candidates upfront.
Data Source
AI summary
A method of determining a therapeutic regimen in a patient with cancer comprising determining in a sample from the patient the tumor mutation burden (TMB) and loss of heterozygosity (LOH), wherein high TMB in combination with no LOH is indicative of a positive outcome when treated with a checkpoint inhibitor and high TMB with LOH is indicative of a poor outcome, is provided herein.